The secondary endpoints were improvement in a number
of recognized clinical scales, as an indirect measureof improved compliance: Positive and Negative Syndrome
Scale’s (PANSS) remission criteria [25], Global Assessment of
Functioning Scale (GAF) [33], and SubjectiveWell-Being on
Neuroleptic Treatment Scale (SWN) [34].
The UKU side effects rating scale (UKU) [35] was also
used as the presence of side effects indicates actual consumption
of the medication.
The tertiary endpoints were time from discharge to
first rehospitalization and bed day consumption within 12
months.